Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase III trial of OPF-109 vs active control TPN in chronic renal failure requiring central parenteral nutrition
jRCT2051190070Phase 3Completed
- Sponsor
- Otsuka Pharmaceutical Factory, Inc.
- Start
- Nov 2019
- Countries
- 1
01
Overview
Phase 3, randomised trial of OPF-109 in chronic kidney disease (CKD) (2 arms), sponsored by Otsuka Pharmaceutical Factory, Inc. Primary endpoints: PROT at day 8, ALB at day 8 and 2 more. Started Nov 2019; status: completed.
02
Drugs
OPF-109
03
Conditions
chronic kidney disease (CKD)
Beyond the preview
Go deeper on jRCT2051190070.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2051190070.